By Thomas Lee
If the Food & Drug Administration has been too cozy with medical device companies in recent years, as some critics charge, Uromedica Inc. must have been missed the memo.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
By Thomas Lee
If the Food & Drug Administration has been too cozy with medical device companies in recent years, as some critics charge, Uromedica Inc. must have been missed the memo.
American Medical Systems Holdings Inc. (NSDQ:AMMD) posted fourth-quarter sales of $146 million for the three months ended Jan. 2, up 9 percent compared with $134 million during the same period last year. Net income rose more than 136 percent to $22.3 million, compared with $9.4 million during Q4 2008:
American Medical Systems Confirms Fourth Quarter Revenue and Finishes
2009 with Strong Financial Performance
Q-Med AB (STO:QMED) posted sales of about $179.1 million last year, up 7.2 percent compared with roughly $167.1 million during 2008. Annual net income rose 1,976 percent to approximately $90 million, compared with about $4.3 million during 2008.
Fourth-quarter sales were roughly $49.6 million, up 3.6 percent compared with $47.9 million during Q4 2008. Net income was $7.3 million for the quarter, compared with a net loss of $6.3 millio during the same period in 2008:
2010-02-12 08:31
January – December
A federal appeals court cleared Intuitive Surgical Inc. (NSDQ:ISRG) of any liability in a lawsuit alleging that one of its malfunctioning da Vinci surgical robots caused a Pennsylvania man’s erectile dysfunction.
Roland Mracek sued Intuitive after undergoing a prostatectomy at Bryn Mawr hospital in June 2005. During the surgery, the da Vinci robot went on the fritz and displayed error messages; after his surgical team and an Intuitive rep couldn’t make the robot work, surgeons performed a traditional laparoscopic prostatectomy, according to court documents. A week later Mracek suffered an episode of gross hematuria (visible blood in the urine) and later developed severe groin pain and erectile dysfunction.
Uroplasty Inc. (NYSE:UPI) posted third-quarter sales of $3.1 million for the three months ended Dec. 31, 2009, down 9.4 percent compared with $3.4 million during the same period last year. UPI slashed its net loss 57 percent to $387,000, compared with $894,000 during Q3 2009:
C.R. Bard Inc. (NYSE:CRB) rode strong sales growth in its vascular and surgical specialties businesses to a 10 percent bump to its bottom line last year, despite the fact that its net income shrunk about 30 percent during the fourth quarter.
For the three months ended Dec. 31, 2009, the Murray Hill, N.J.-based medical devices giant reported a $106 million profit on $676 million in sales, down 29 percent compared to $150 million in net income on $634 million in sales for the same period last year. A more than 250 percent increase in its tax provision was the difference-maker for the firm, accounting for about $40 million in costs.
Rochester Medical Corp. (NSDQ:ROCM) posted record first-quarter sales of $10.2 million for the three months ended Dec. 31, 2009, up 21.3 percent compared with $8.4 million during the same period last year. Despite the record sales, Rochester Medical posted a net loss of nearly $170,000 for the quarter, compared with net income of about $54,000 during Q1 2009:
STEWARTVILLE, Minn., Jan 26, 2010 /PRNewswire via COMTEX/ — Rochester Medical Corporation (Nasdaq: ROCM) today announced operating results for its first quarter ended December 31, 2009.
Urologix Inc. (NSDQ:ULGX) posted second-quarter sales of $4.1 million for the three months ended Dec. 31, 2009, up 20 percent compared with $3.4 million during the same period in 2008. Urologix posted a net loss of $273,000 for the quarter, compared with a net loss of $1.1 million during Q2 2008:
Taris Biomedical tapped Julie Lekstrom Himes to be its chief medical officer and lead its clinical development program.
Rochester Medical Corp. posted third-quarter sales of $9 million for the three months ended Sept. 30, down 5.3 percent compared with $9.5 million during the same period last year. The company posted net losses of $229,000 for the quarter, compared with net income of $342,000 during Q3 2008:
Augmenix, the latest life science venture from serial hydrogel entrepreneur Amar Sawhney, landed a second, $6.1 million tranche for a Series B funding round to develop its SpaceOAR radiation oncology polymer product.
Waltham, Mass.-based Augmenix is working on clinical trials for the product, an injectable, degradable polyethylene glycol-based hydrogel designed to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer.